CombiGene Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Peter Ekolind

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.6yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Peter Ekolind (59 yo)

less than a year

Tenure

Mr. Peter Ekolind served as Chief Operating Officer at CombiGene AB (publ) since September 27, 2022 and serves as its Chief Executive Officer since September 01, 2023. He serves as Chief Executive Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Ekolind	Chief Executive Officer	less than a year	no data	no data
David Woldbye	Scientific Founder	no data	no data	no data
Merab Kokaia	Scientific Founder	no data	no data	no data
Louise Aspenberg	Chief Financial Officer	4.3yrs	no data	no data
Karin Agerman	Chief Scientific Officer	1.6yrs	kr609.69k	no data

1.6yrs

Average Tenure

59yo

Average Age

Experienced Management: COMBI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Gunilla Lundmark	Independent Director	3yrs	kr125.00k	no data
Jonas Ekblom	Independent Chairman of the Board	4.3yrs	kr179.94k	no data
Andrew Rice	Member of Scientific Advisory Board	less than a year	no data	no data
Peter Nilsson	Independent Director	10.3yrs	kr178.64k	0.39% SEK 281.9k
Annamaria Vezzani	Member of Scientific Advisory Board	no data	no data	no data
Margitta Seeck	Member of Scientific Advisory Board	no data	no data	no data
Per Lundin	Independent Director	4.3yrs	kr125.00k	0.030% SEK 21.8k
Malin Almgren	Independent Director	1.3yrs	no data	no data
David Bennett	Member of Scientific Advisory Board	less than a year	no data	no data
Lars Arendt-Nielsen	Member of Scientific Advisory Board	less than a year	no data	no data

2.2yrs

Average Tenure

53yo

Average Age

Experienced Board: COMBI's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

CombiGene Management

Management criteria checks 0/4

Key information

Recent management updates

CombiGene AB (publ), Annual General Meeting, May 23, 2024

High number of new and inexperienced directors

CombiGene AB (publ) Announces Chief Executive Officer Changes

High number of new and inexperienced directors

CombiGene Appoints Peter Ekolind as COO

High number of new and inexperienced directors

Recent updates

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Full year 2023 earnings released: kr1.80 loss per share (vs kr0.31 loss in FY 2022)

CombiGene AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)

CombiGene AB (publ), Annual General Meeting, May 23, 2024

New major risk - Share price stability

New major risk - Market cap size

High number of new and inexperienced directors

Second quarter 2023 earnings released: kr0.32 loss per share (vs kr0.23 profit in 2Q 2022)

CombiGene AB (publ) Announces Chief Executive Officer Changes

First quarter 2023 earnings released: kr0.74 loss per share (vs kr0.14 loss in 1Q 2022)

Full year 2022 earnings released: kr0.31 loss per share (vs kr1.21 profit in FY 2021)

CombiGene AB (publ) to Report Q1, 2023 Results on May 12, 2023

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: kr0.20 (vs kr0.62 loss in 3Q 2021)

Investor sentiment improved over the past week

CombiGene Appoints Peter Ekolind as COO

Second quarter 2022 earnings released: EPS: kr0.23 (vs kr1.18 loss in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: kr0.14 loss per share (vs kr0.95 loss in 1Q 2021)

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

CombiGene AB (publ), Annual General Meeting, May 19, 2022

CombiGene's (STO:COMBI) Earnings Are Weaker Than They Seem

Combigene AB (Publ) Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study

Is CombiGene (STO:COMBI) In A Good Position To Invest In Growth?

Board Member recently bought kr100k worth of stock

New 90-day low: kr0.51

CombiGene Announces the Material from the First Large-Scale Production of CG01 Now Released for Use in the Final Parts of the Preclinical Program

We Think CombiGene (STO:COMBI) Can Afford To Drive Business Growth

CEO & Director exercised options to buy kr82k worth of stock.

Third quarter 2020 earnings released: kr0.045 loss per share

New 90-day low: kr0.61

CombiGene Announces Update on Lipodystrophy Project CGT2

New 90-day low: kr0.64

New 90-day low: kr0.80

Earnings released

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age